<p>藥明康德（NASDAQ:DXCM - 獲取免費報告）在週一發佈的報告中，巴克萊的投資分析師將其目標價格從 100.00 美元下調至 80.00 美元，Benzinga 報道。該公司目前對這家醫療設備公司的股票給予 “買入” 評級。巴克萊的目標價格表明該股票的潛在上漲幅度為 24.46%。</p>
<ul>
<li>五月賣出，遠離市場——從這三隻股票開始</li>
</ul>
<p>其他股票研究分析師也對該股票發佈了報告。花旗集團在 5 月 4 日的報告中重新發布了 “買入” 評級，並將藥明康德的目標價格下調至 79.00 美元（之前為 84.00 美元）。TD Cowen 在 5 月 1 日的研究報告中將藥明康德的目標價格從 84.00 美元下調至 75.00 美元，並對該股票給予 “買入” 評級。瑞穗證券在 5 月 1 日的研究報告中設定了藥明康德 75.00 美元的目標價格。雷蒙德·詹姆斯金融在 5 月 1 日的研究報告中設定了藥明康德 81.00 美元的目標價格。最後，Evercore 將藥明康德的評級從 “持平” 上調至 “跑贏大盤”，並在 3 月 24 日的研究報告中設定了 90.00 美元的目標價格。三位研究分析師對該股票給予了強烈買入評級，十九位給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，藥明康德目前的平均評級為 “適度買入”，平均目標價格為 82.21 美元。</p>
<p><strong>查看我們關於 DXCM 的最新報告</strong></p>
<h2>藥明康德股票表現</h2>
<ul>
<li>分析師喜愛藥明康德的三大理由</li>
</ul>
<p>在週一的午盤交易中，藥明康德的股票上漲了 2.65 美元，達到了 64.28 美元。該股票的交易量為 5,059,238 股，而其平均交易量為 5,045,384 股。該公司的 50 日移動平均線為 63.46 美元，200 日移動平均線為 65.85 美元。公司市值為 248 億美元，市盈率為 27.43，市盈增長比率為 1.06，貝塔值為 1.40。藥明康德的 52 周低點為 54.11 美元，52 周高點為 89.98 美元。該公司的流動比率為 1.95，速動比率為 1.64，債務與股本比率為 0.42。</p>
<p>藥明康德（NASDAQ:DXCM - 獲取免費報告）最後一次發佈財報是在 4 月 30 日，醫療設備公司報告每股收益（EPS）為 0.56 美元，超出市場共識預期的 0.47 美元，超出幅度為 0.09 美元。該公司在該季度的收入為 11.9 億美元，而分析師預期為 11.7 億美元。藥明康德的淨利潤率為 19.31%，股本回報率為 33.33%。該公司的季度收入較去年同期增長了 15.0%。在去年同期，該公司每股收益為 0.32 美元。研究分析師平均預測藥明康德在當前年度的每股收益為 2.56 美元。</p>
<h2>內部買賣情況</h2>
<ul>
<li>從分紅到增長：為什麼這三隻股票在 2025 年脱穎而出</li>
</ul>
<p>在其他新聞中，執行副總裁 Michael Jon Brown 在 4 月 15 日的交易中出售了 1,700 股該股票。該股票的平均售價為 63.04 美元，總交易額為 107,168.00 美元。交易完成後，該執行副總裁直接持有公司 111,204 股，價值約為 7,010,300.16 美元。這代表其持股比例下降了 1.51%。該交易已在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，董事 Bridgette P. Heller 在 5 月 12 日的交易中出售了 1,012 股該股票。該股票的平均售價為 60.01 美元，總價值為 60,730.12 美元。交易完成後，該董事持有公司 25,007 股，價值為 1,500,670.07 美元。這代表其持股比例下降了 3.89%。該銷售的 SEC 文件提供了更多信息。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士在上個季度共出售了 4,412 股公司股票，價值為 278,143 美元。公司內部人士目前持有 0.28% 的公司股票。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金和其他機構投資者最近調整了對該公司的持股。佛蒙特信託公司在第四季度將其在藥明康德的持股增加了 14.8%。佛蒙特信託公司目前持有 1,122 股醫療設備公司的股票，價值 74,000 美元，此前在上個季度增持了 145 股。CVA 家族辦公室在第四季度將其在藥明康德的持股增加了 48.5%。CVA 家族辦公室目前持有 450 股醫療設備公司的股票，價值 30,000 美元，此前在上個季度增持了 147 股。V Square 定量管理公司在第一季度將其在藥明康德的持股增加了 1.8%。V Square 定量管理公司目前持有 9,618 股醫療設備公司的股票，價值 604,000 美元，此前在上個季度增持了 172 股。埃塞克斯金融服務公司在第一季度將其在藥明康德的持股增加了 5.7%。埃塞克斯金融服務公司目前持有 3,256 股醫療設備公司的股票，價值 204,000 美元，此前在上個季度增持了 175 股。最後，IFP Advisors Inc 在第三季度將其在藥明康德的持股增加了 24.7%。IFP Advisors Inc 目前持有 900 股醫療設備公司的股票，價值 61,000 美元，此前在該期間增持了 178 股。97.75% 的股票目前由機構投資者持有。</p>
<h2>藥明康德公司簡介</h2>
<p>（獲取免費報告）</p>
<p>DexCom, Inc 是一家醫療設備公司，開發、製造和分銷用於糖尿病患者的連續血糖監測（CGM）系統。其產品旨在提供近實時的血糖讀數、趨勢信息和警報，以幫助患者和臨牀醫生管理胰島素劑量，減少低血糖和高血糖。該公司的產品結合了可穿戴血糖傳感器、無線發射器和軟件應用，將數據傳輸到智能手機、專用接收器和基於雲的平台，以便進行遠程監測。</p>
<p>DexCom 成立於 1999 年，總部位於加利福尼亞州聖地亞哥，專注於推進 CGM 技術，並擴大臨牀應用，超越傳統的胰島素依賴人羣。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 DexCom 更好</li>
<li>為什麼 Applied Optoelectronics 的股票可能接近轉折點</li>
<li>從高收益到高增長：3 只提升股息的股票</li>
<li>Everspin Technologies 會是下一個 AI 邊緣突破嗎？</li>
<li>5 只機器人股票值得關注，因為物理 AI 正在蓬勃發展</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 DexCom 嗎？</h2>
<p>在考慮 DexCom 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 DexCom 並不在名單上。</p>
<p>雖然 DexCom 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

德康醫療

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>美國銀行已將德康醫療（NASDAQ:DXCM）的目標股價從 100.00 美元下調至 80.00 美元，同時維持 “買入” 評級。其他分析師也調整了他們的目標，花旗集團設定的目標為 79.00 美元，TD Cowen 為 75.00 美元。德康醫療的股票目前交易價格為 64.28 美元，較新目標有 24.46% 的上漲潛力。該公司報告每股收益為 0.56 美元，超出預期，市值為 248 億美元</p>

<p>DexCom (NASDAQ:DXCM - Get Free Report) had its target price reduced by investment analysts at Bank of America from $100.00 to $80.00 in a report issued on Monday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the medical device company's stock. Bank of America's price target points to a potential upside of 24.46% from the stock's current price.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:DXCM - 獲取免費報告）在週一發佈的報告中，巴克萊的投資分析師將其目標價格從 100.00 美元下調至 80.00 美元，Benzinga 報道。該公司目前對這家醫療設備公司的股票給予 “買入” 評級。巴克萊的目標價格表明該股票的潛在上漲幅度為 24.46%。</p>
</div><ul>
<li>Sell in May and Go Away—Starting With These 3 Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>五月賣出，遠離市場——從這三隻股票開始</li>
</ul>
</div><p>Other equities research analysts have also issued reports about the stock. Citigroup reissued a &#34;buy&#34; rating and issued a $79.00 target price (down from $84.00) on shares of DexCom in a report on Monday, May 4th. TD Cowen reduced their price objective on shares of DexCom from $84.00 to $75.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, May 1st. Mizuho set a $75.00 price objective on shares of DexCom in a research report on Friday, May 1st. Raymond James Financial set a $81.00 price objective on shares of DexCom in a research report on Friday, May 1st. Finally, Evercore upgraded shares of DexCom from an &#34;in-line&#34; rating to an &#34;outperform&#34; rating and set a $90.00 price objective on the stock in a research report on Tuesday, March 24th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, DexCom presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $82.21.</p>
<div class="lb-trans"><p>其他股票研究分析師也對該股票發佈了報告。花旗集團在 5 月 4 日的報告中重新發布了 “買入” 評級，並將藥明康德的目標價格下調至 79.00 美元（之前為 84.00 美元）。TD Cowen 在 5 月 1 日的研究報告中將藥明康德的目標價格從 84.00 美元下調至 75.00 美元，並對該股票給予 “買入” 評級。瑞穗證券在 5 月 1 日的研究報告中設定了藥明康德 75.00 美元的目標價格。雷蒙德·詹姆斯金融在 5 月 1 日的研究報告中設定了藥明康德 81.00 美元的目標價格。最後，Evercore 將藥明康德的評級從 “持平” 上調至 “跑贏大盤”，並在 3 月 24 日的研究報告中設定了 90.00 美元的目標價格。三位研究分析師對該股票給予了強烈買入評級，十九位給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，藥明康德目前的平均評級為 “適度買入”，平均目標價格為 82.21 美元。</p>
</div><p><strong>View Our Latest Report on DXCM</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 DXCM 的最新報告</strong></p>
</div><h2>DexCom Stock Performance</h2>
<div class="lb-trans"><h2>藥明康德股票表現</h2>
</div><ul>
<li>3 Reasons Analysts Love DexCom</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師喜愛藥明康德的三大理由</li>
</ul>
</div><p>DexCom stock traded up $2.65 during midday trading on Monday, hitting $64.28. The stock had a trading volume of 5,059,238 shares, compared to its average volume of 5,045,384. The firm's fifty day moving average is $63.46 and its two-hundred day moving average is $65.85. The company has a market capitalization of $24.80 billion, a PE ratio of 27.43, a P/E/G ratio of 1.06 and a beta of 1.40. DexCom has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.</p>
<div class="lb-trans"><p>在週一的午盤交易中，藥明康德的股票上漲了 2.65 美元，達到了 64.28 美元。該股票的交易量為 5,059,238 股，而其平均交易量為 5,045,384 股。該公司的 50 日移動平均線為 63.46 美元，200 日移動平均線為 65.85 美元。公司市值為 248 億美元，市盈率為 27.43，市盈增長比率為 1.06，貝塔值為 1.40。藥明康德的 52 周低點為 54.11 美元，52 周高點為 89.98 美元。該公司的流動比率為 1.95，速動比率為 1.64，債務與股本比率為 0.42。</p>
</div><p>DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm's quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 EPS. On average, research analysts forecast that DexCom will post 2.56 EPS for the current year.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:DXCM - 獲取免費報告）最後一次發佈財報是在 4 月 30 日，醫療設備公司報告每股收益（EPS）為 0.56 美元，超出市場共識預期的 0.47 美元，超出幅度為 0.09 美元。該公司在該季度的收入為 11.9 億美元，而分析師預期為 11.7 億美元。藥明康德的淨利潤率為 19.31%，股本回報率為 33.33%。該公司的季度收入較去年同期增長了 15.0%。在去年同期，該公司每股收益為 0.32 美元。研究分析師平均預測藥明康德在當前年度的每股收益為 2.56 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣情況</h2>
</div><ul>
<li>From Dividends to Growth: Why These 3 Stocks Stand Out in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>從分紅到增長：為什麼這三隻股票在 2025 年脱穎而出</li>
</ul>
</div><p>In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares in the company, valued at approximately $7,010,300.16. This represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares of the company's stock, valued at $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,412 shares of company stock valued at $278,143 over the last quarter. Corporate insiders own 0.28% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，執行副總裁 Michael Jon Brown 在 4 月 15 日的交易中出售了 1,700 股該股票。該股票的平均售價為 63.04 美元，總交易額為 107,168.00 美元。交易完成後，該執行副總裁直接持有公司 111,204 股，價值約為 7,010,300.16 美元。這代表其持股比例下降了 1.51%。該交易已在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，董事 Bridgette P. Heller 在 5 月 12 日的交易中出售了 1,012 股該股票。該股票的平均售價為 60.01 美元，總價值為 60,730.12 美元。交易完成後，該董事持有公司 25,007 股，價值為 1,500,670.07 美元。這代表其持股比例下降了 3.89%。該銷售的 SEC 文件提供了更多信息。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士在上個季度共出售了 4,412 股公司股票，價值為 278,143 美元。公司內部人士目前持有 0.28% 的公司股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the company. Trust Co. of Vermont boosted its position in shares of DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company's stock valued at $74,000 after acquiring an additional 145 shares during the last quarter. CVA Family Office LLC boosted its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock valued at $30,000 after acquiring an additional 147 shares during the last quarter. V Square Quantitative Management LLC boosted its position in shares of DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company's stock valued at $604,000 after acquiring an additional 172 shares during the last quarter. Essex Financial Services Inc. boosted its position in shares of DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company's stock valued at $204,000 after acquiring an additional 175 shares during the last quarter. Finally, IFP Advisors Inc boosted its stake in DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company's stock worth $61,000 after buying an additional 178 shares during the period. 97.75% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近調整了對該公司的持股。佛蒙特信託公司在第四季度將其在藥明康德的持股增加了 14.8%。佛蒙特信託公司目前持有 1,122 股醫療設備公司的股票，價值 74,000 美元，此前在上個季度增持了 145 股。CVA 家族辦公室在第四季度將其在藥明康德的持股增加了 48.5%。CVA 家族辦公室目前持有 450 股醫療設備公司的股票，價值 30,000 美元，此前在上個季度增持了 147 股。V Square 定量管理公司在第一季度將其在藥明康德的持股增加了 1.8%。V Square 定量管理公司目前持有 9,618 股醫療設備公司的股票，價值 604,000 美元，此前在上個季度增持了 172 股。埃塞克斯金融服務公司在第一季度將其在藥明康德的持股增加了 5.7%。埃塞克斯金融服務公司目前持有 3,256 股醫療設備公司的股票，價值 204,000 美元，此前在上個季度增持了 175 股。最後，IFP Advisors Inc 在第三季度將其在藥明康德的持股增加了 24.7%。IFP Advisors Inc 目前持有 900 股醫療設備公司的股票，價值 61,000 美元，此前在該期間增持了 178 股。97.75% 的股票目前由機構投資者持有。</p>
</div><h2>DexCom Company Profile</h2>
<div class="lb-trans"><h2>藥明康德公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.</p>
<div class="lb-trans"><p>DexCom, Inc 是一家醫療設備公司，開發、製造和分銷用於糖尿病患者的連續血糖監測（CGM）系統。其產品旨在提供近實時的血糖讀數、趨勢信息和警報，以幫助患者和臨牀醫生管理胰島素劑量，減少低血糖和高血糖。該公司的產品結合了可穿戴血糖傳感器、無線發射器和軟件應用，將數據傳輸到智能手機、專用接收器和基於雲的平台，以便進行遠程監測。</p>
</div><p>Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.</p>
<div class="lb-trans"><p>DexCom 成立於 1999 年，總部位於加利福尼亞州聖地亞哥，專注於推進 CGM 技術，並擴大臨牀應用，超越傳統的胰島素依賴人羣。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than DexCom</li>
<li>Why Applied Optoelectronics Stock May Be Near a Turning Point</li>
<li>From High-Yield to High-Growth: 3 Stocks Boosting Dividends</li>
<li>Is Everspin Technologies the Next AI Edge Breakout?</li>
<li>5 Robotics Stocks to Watch as Physical AI Builds Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 DexCom 更好</li>
<li>為什麼 Applied Optoelectronics 的股票可能接近轉折點</li>
<li>從高收益到高增長：3 只提升股息的股票</li>
<li>Everspin Technologies 會是下一個 AI 邊緣突破嗎？</li>
<li>5 只機器人股票值得關注，因為物理 AI 正在蓬勃發展</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=DXCM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DexCom Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 DexCom 嗎？</h2>
</div><p>Before you consider DexCom, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 DexCom 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 DexCom 並不在名單上。</p>
</div><p>While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 DexCom 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bank of America Lowers DexCom (NASDAQ:DXCM) Price Target to $80.00

Market Beat

2 倍做多納斯達克生物技術 ETF - ProShares

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

標普生物技術 3 倍做多 - Direxion

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

美國銀行

花旗

瑞穗金融集團

Mizuho Financial Group, Inc.

瑞傑金融

Evercore

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

美國銀行將德康醫療（NASDAQ:DXCM）的目標股價下調至 80 美元